Table 5.
Net Reclassification Improvement of gene expression profile versus other prognostic tools.
| All cases | At 2 years | At 3 years | |
|---|---|---|---|
| TNM Staging | |||
| Sample size | 425 | 146 | 70 |
| Positive for metastasis | 43 (10%) | 32 (22%) | 42 (60%) |
| Net Reclassification Improvement | 0.42 | 0.37 | 0.43 |
| Standard Error | 0.044 | 0.055 | 0.066 |
| Significance level | P < 0.0001 | P = 0.008 | P = 0.001 |
| Monosomy 3 | |||
| Sample size | 260 | 121 | 60 |
| Positive for metastasis | 38 (15%) | 27 (22%) | 37 (62%) |
| Net Reclassification Improvement | 0.28 | 0.36 | 0.38 |
| Standard Error | 0.038 | 0.052 | 0.065 |
| Significance level | P = 0.002 | P = 0.006 | P = 0.004 |
TNM = Tumor/Node/Metastasis: the tumor classification guidelines for uveal melanoma established by the American Joint Committee on Cancer. Two and three year subanalyses represent data known at those time points following primary treatment in evaluable cases.